Turtle Cameron, Spyre Therapeutics’ CEO, sold 15,000 shares across four transactions priced from $86.36 to $89.07 per share. The post-transaction ownership figure was 552,540 shares, giving investors the reported scale of Cameron’s remaining position after the sale.
Key Highlights
- The transactions took place on 1 September 2026.
- Each of the four transactions carried transaction code S.
- Turtle Cameron was identified as Spyre Therapeutics’ chief executive officer.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) CEO Turtle Cameron sold 15,000 shares at prices ranging from $86.36 to $89.07 per share. Cameron’s reported ownership after the transactions stood at 552,540 shares.
Four Transactions Completed on September 1
Cameron completed the sales through four separate transactions involving Spyre Therapeutics shares. Each transaction used transaction code S. The transactions occurred on 1 September 2026. Cameron is identified as Spyre Therapeutics’ chief executive officer. The reported prices extended from $86.36 to $89.07 per share across the transactions. The total Volume sold was 15,000 shares.
Post-Transaction Ownership Listed at 552,540 Shares
That post-transaction figure is stated separately from the 15,000 shares sold. The ownership figure records Cameron’s reported position following the four sales.
FAQs
Q: How many Spyre Therapeutics shares did Turtle Cameron sell?
A: Turtle Cameron sold 15,000 Spyre Therapeutics shares. The sales occurred across four separate transactions priced between $86.36 and $89.07 per share.
Q: What was Turtle Cameron’s ownership after the SYRE stock sale?
A: Cameron owned 552,540 Spyre Therapeutics shares after the transactions. Cameron is identified as the company’s chief executive officer. The ownership figure was reported following the four transactions.
Q: When did the Spyre Therapeutics CEO share sale occur?
A: The Spyre Therapeutics CEO share sale took place on 1 September 2026. All four transactions carried transaction code S. The filing reported the sales across four separate transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.